FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100226781> ?p ?o ?g. }

• W3100226781 abstract "Background Natural killer (NK) cells are highly effective and fast-acting cytolytic cells capable of eradicating target cells with limited adverse effects such as cytokine release syndrome (CRS) or graft-versus-host disease. Chimeric antigen receptors (CARs)-engineered NK cells have been recently used against leukemia with encouraging clinical outcomes. 1 The surface antigen CD19, expressed by B-lymphoblasts, represents an ideal CAR target against B cell acute lymphoblastic leukemia (B-ALL). We developed a highly potent CD19 -directed CAR NK cell therapy, NKX019, with an extended in vivo half-life aimed at killing CD19-expressing target. Methods NK cells isolated from healthy PBMCs were expanded in the presence of NKSTIM cells, IL-2, IL-12, IL-18 and transduced with both a CD19-targeted CAR construct and a membrane-bound form of IL-15 (mbIL-15). Control (non-engineered) NK cells were produced in parallel. Cytotoxic activity of NKX019 against CD19+ B-ALL cell line (REH), pre-B ALL cell line (Nalm-6), allogeneic PBMCs was assessed using Incucyte® or flow cytometry. NSG mice bearing either Nalm-6.fluc (Nalm6) or REH.fluc (REH) tumor received different concentrations of NKX019 or control NK cells. In-life analysis of tumor-bearing and naïve NSG mice include: 1) bioluminescence imaging, 2) clinical observations, 3) serum cytokines and 4) CAR+ NK cell persistency. Results NKX019 showed enhanced cytolytic activity against REH and Nalm-6 tumor cells compared to control NK cells and CAR19+ T cells. The superiority of NKX019 over CAR19+ T cells was more pronounced at the earlier time point (24 hours) with near identical calculated EC50 observed at 72 hours for both cell types. Increased cytolytic activity of NKX019 was limited to CD19+ cells in bulk PBMCs. Consistent with our in vitro observations, NKX019 controlled Nalm-6 and REH tumor growth in doses as low as 2 × 106 cells/kg for up to 30 days with no apparent increase in cytokines commonly associated with CRS. Increased Nalm-6 tumor growth coincided with an apparent decrease in measurable NKX019 in the periphery. In tumor-naïve NSG mice, NKX019 was detectable in the blood for up to 9 weeks post-infusion consistent with its extended half-life. Conclusions NKX019 expresses mbIL-15 and is produced in the presence of IL-12 and IL-18, resulting in enhanced in vitro expansion and longer in vivo half-life than non-engineered NK cells. NKX019 also exhibited advantages compared to CAR19+ T cells including faster cytotoxic kinetics and limited production of cytokines associated with CRS. A first-in-human trial of NKX019 in B cell malignancies is planned for 2021. Ethics Approval The animal procedures described in this abstract were conducted in accordance with Explora BioLabs Animal Care and Use Protocol approved by Explora BioLabs Institutional Animal Care and Use Committee. Reference Liu, et al. 2020 NEJM" @default.
• W3100226781 created "2020-11-23" @default.
• W3100226781 creator A5007756951 @default.
• W3100226781 creator A5012802940 @default.
• W3100226781 creator A5015730920 @default.
• W3100226781 creator A5031348605 @default.
• W3100226781 creator A5041317259 @default.
• W3100226781 creator A5042586940 @default.
• W3100226781 creator A5044519846 @default.
• W3100226781 creator A5044693959 @default.
• W3100226781 creator A5045664700 @default.
• W3100226781 creator A5050613603 @default.
• W3100226781 creator A5055010467 @default.
• W3100226781 creator A5062110929 @default.
• W3100226781 creator A5064836349 @default.
• W3100226781 creator A5073427642 @default.
• W3100226781 creator A5074085834 @default.
• W3100226781 creator A5084572579 @default.
• W3100226781 creator A5088048815 @default.
• W3100226781 creator A5089638734 @default.
• W3100226781 date "2020-11-01" @default.
• W3100226781 modified "2023-10-16" @default.
• W3100226781 title "127 Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell" @default.
• W3100226781 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0127" @default.
• W3100226781 hasPublicationYear "2020" @default.
• W3100226781 type Work @default.
• W3100226781 sameAs 3100226781 @default.
• W3100226781 citedByCount "1" @default.
• W3100226781 countsByYear W31002267812022 @default.
• W3100226781 crossrefType "journal-article" @default.
• W3100226781 hasAuthorship W3100226781A5007756951 @default.
• W3100226781 hasAuthorship W3100226781A5012802940 @default.
• W3100226781 hasAuthorship W3100226781A5015730920 @default.
• W3100226781 hasAuthorship W3100226781A5031348605 @default.
• W3100226781 hasAuthorship W3100226781A5041317259 @default.
• W3100226781 hasAuthorship W3100226781A5042586940 @default.
• W3100226781 hasAuthorship W3100226781A5044519846 @default.
• W3100226781 hasAuthorship W3100226781A5044693959 @default.
• W3100226781 hasAuthorship W3100226781A5045664700 @default.
• W3100226781 hasAuthorship W3100226781A5050613603 @default.
• W3100226781 hasAuthorship W3100226781A5055010467 @default.
• W3100226781 hasAuthorship W3100226781A5062110929 @default.
• W3100226781 hasAuthorship W3100226781A5064836349 @default.
• W3100226781 hasAuthorship W3100226781A5073427642 @default.
• W3100226781 hasAuthorship W3100226781A5074085834 @default.
• W3100226781 hasAuthorship W3100226781A5084572579 @default.
• W3100226781 hasAuthorship W3100226781A5088048815 @default.
• W3100226781 hasAuthorship W3100226781A5089638734 @default.
• W3100226781 hasConcept C129374314 @default.
• W3100226781 hasConcept C147483822 @default.
• W3100226781 hasConcept C149532602 @default.
• W3100226781 hasConcept C154317977 @default.
• W3100226781 hasConcept C171122931 @default.
• W3100226781 hasConcept C202751555 @default.
• W3100226781 hasConcept C203014093 @default.
• W3100226781 hasConcept C206191192 @default.
• W3100226781 hasConcept C2776090121 @default.
• W3100226781 hasConcept C2778461978 @default.
• W3100226781 hasConcept C2778957590 @default.
• W3100226781 hasConcept C3875195 @default.
• W3100226781 hasConcept C502942594 @default.
• W3100226781 hasConcept C55493867 @default.
• W3100226781 hasConcept C71924100 @default.
• W3100226781 hasConcept C86803240 @default.
• W3100226781 hasConcept C8891405 @default.
• W3100226781 hasConceptScore W3100226781C129374314 @default.
• W3100226781 hasConceptScore W3100226781C147483822 @default.
• W3100226781 hasConceptScore W3100226781C149532602 @default.
• W3100226781 hasConceptScore W3100226781C154317977 @default.
• W3100226781 hasConceptScore W3100226781C171122931 @default.
• W3100226781 hasConceptScore W3100226781C202751555 @default.
• W3100226781 hasConceptScore W3100226781C203014093 @default.
• W3100226781 hasConceptScore W3100226781C206191192 @default.
• W3100226781 hasConceptScore W3100226781C2776090121 @default.
• W3100226781 hasConceptScore W3100226781C2778461978 @default.
• W3100226781 hasConceptScore W3100226781C2778957590 @default.
• W3100226781 hasConceptScore W3100226781C3875195 @default.
• W3100226781 hasConceptScore W3100226781C502942594 @default.
• W3100226781 hasConceptScore W3100226781C55493867 @default.
• W3100226781 hasConceptScore W3100226781C71924100 @default.
• W3100226781 hasConceptScore W3100226781C86803240 @default.
• W3100226781 hasConceptScore W3100226781C8891405 @default.
• W3100226781 hasLocation W31002267811 @default.
• W3100226781 hasOpenAccess W3100226781 @default.
• W3100226781 hasPrimaryLocation W31002267811 @default.
• W3100226781 hasRelatedWork W11987055 @default.
• W3100226781 hasRelatedWork W2094593 @default.
• W3100226781 hasRelatedWork W4041773 @default.
• W3100226781 hasRelatedWork W4985366 @default.
• W3100226781 hasRelatedWork W5116461 @default.
• W3100226781 hasRelatedWork W5846668 @default.
• W3100226781 hasRelatedWork W6149997 @default.
• W3100226781 hasRelatedWork W7741958 @default.
• W3100226781 hasRelatedWork W9571234 @default.
• W3100226781 hasRelatedWork W9820864 @default.
• W3100226781 isParatext "false" @default.
• W3100226781 isRetracted "false" @default.
• W3100226781 magId "3100226781" @default.
• W3100226781 workType "article" @default.